Santen Pharmaceutical-Un ADRSNPHY
13F holders, Q4 2024 (December 31)3holders +1
1new positions
0sold out
$10.28avg. 13F price*
At the end of Q4 2024, 3 institutions reported holding Santen Pharmaceutical-Un ADR (SNPHY) in their 13F filings, up 1 from Q3 2024. 1 opened new positions and 0 sold out. The largest holders were Copeland Capital Management, LLC ($2K), Rhumbline Advisers ($303) and PNC Financial Services Group, Inc. ($268).
- Company
- Santen Pharmaceutical-Un ADR
- CUSIP
- 80287P100
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $2K |
| Exits | 0 | $0 |
All 13F filers, Q3 2024 → Q4 2024: 230 shares bought, net +230 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Copeland Capital Management, LLC | 0.00% | New | 230 | $2K |
| Rhumbline Advisers | 0.00% | No change | 30 | $303 |
| PNC Financial Services Group, Inc. | 0.00% | No change | 26 | $268 |
"% of holder's portfolio" is SNPHY's weight in each manager's 13F, not the share of Santen Pharmaceutical-Un ADR the manager owns.